Table 2. Comparison of various clinical factors before and after treatment.
| Variable | Atorvastatin 10 mg (n=23) | Atorvastatin 40 mg (n=27) | ||||
|---|---|---|---|---|---|---|
| Before | After | P valuea | Before | After | P valuea | |
| CPK, U/L | 113.8±94.0 | 131.9±136.0 | 0.459 | 104.0±43.7 | 96.5±46.4 | 0.306 |
| AST, IU/L | 22.7±16.0 | 24.2±14.9 | 0.190 | 21.4±9.3 | 21.8±8.4 | 0.647 |
| ALT, IU/L | 25.9±19.9 | 26.8±16.6 | 0.312 | 27.0±17.0 | 27.4±14.8 | 0.484 |
| Insulin, µIU/mL | 13.6±11.5 | 10.8±8.3 | 0.171 | 21.6±45.6 | 14.3±15.3 | 0.377 |
| C-peptide, pmol/mL | 1.1±0.7 | 0.9±0.5 | 0.322 | 1.2±1.1 | 1.0±0.6 | 0.201 |
| HbA1c, % | 7.6±1.6 | 7.3±1.2 | 0.235 | 7.3±1.8 | 7.2±1.4 | 0.562 |
| Glucose, mg/dL | 158.9±53.0 | 154.2±62.0 | 0.110 | 167.9±75.0 | 144.0±49.0 | 0.053 |
| TC, mg/dL | 209.1±30.0 | 148.2±24.1 | <0.001 | 211.0±22.8 | 132.3±26.2 | <0.001 |
| LDL-C, mg/dL | 138.6±23.9 | 82.7±18.8 | <0.001 | 139.5±24.2 | 68.0±22.7 | <0.001 |
| HDL-C, mg/dL | 48.7±12.3 | 47.3±10.7 | 0.551 | 46.7±10.6 | 47.6±11.8 | 0.977 |
| TG, mg/dL | 181.3±93.1 | 133.7±75.9 | 0.012 | 191.3±117.4 | 129.8±62.6 | 0.001 |
| GDF-15, pg/mL | 1,460.6±874.8 | 1,451.0±770.8 | 0.745 | 1,271.6±801.0 | 1,341.4±855.2 | 0.665 |
| HOMA-IR | 5.1±4.0 | 4.2±4.8 | 0.463 | 6.5±9.6 | 4.9±4.7 | 0.253 |
| hsCRP, mg/dL | 2.6±2.7 | 1.3±1.1 | 0.020 | 2.3±2.6 | 1.0±0.7 | 0.018 |
Values are presented as mean±standard deviation.
CPK, creatine phosphokinase; AST, aspartate transaminase; ALT, alanine transaminase; HbA1c, glycosylated hemoglobin; TC, total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglyceride; GDF-15, growth differentiation factor 15; HOMA-IR, homeostasis model assessment-estimated insulin resistance; hsCRP, high-sensitivity C-reactive protein.
aP value determined using the Wilcoxon signed rank test.